Onco360 Selected for VERZENIO® Limited Distribution Pharmacy Network
2017年10月17日 - 5:15AM
ビジネスワイヤ(英語)
Onco360, the nation’s largest independent Oncology Pharmacy,
announced today that it has been selected to participate in the
limited distribution network for Eli Lilly and Company’s new
product, VERZENIOTM (Abemaciclib), a twice daily oral
cyclin-dependent kinase (CDK) 4/6 inhibitor approved by the U.S.
Food and Drug Administration (FDA). VERZENIO is used in combination
with fulvestrant to treat women with hormone receptor
(HR)–positive, human epidermal growth factor receptor 2
(HER2)–negative advanced breast cancer, or breast cancer that has
spread to other parts of the body (metastatic), whose disease has
progressed after receiving hormonal therapy. VERZENIO is also
approved as a monotherapy to treat adults with HR–positive,
HER2–negative advanced breast cancer, or metastatic breast cancer
whose disease has progressed after receiving hormonal therapy and
chemotherapy in the metastatic setting.
“VERZENIO is a highly anticipated product that provides another
therapy option for patients battling advanced breast cancer,” said
Onco360 President and CEO Paul Jardina. “The world’s top
biopharmaceutical companies, including Eli Lilly, continue to
leverage Onco360’s patient-centric approach to cancer care when
choosing a pharmacy network to distribute their pioneering new
treatments in oncology. We are pleased to have been selected to
join the limited distribution network for VERZENIO and look forward
to providing outstanding care to patients who have a critical need
for this therapy.”
About Onco360 Oncology
Pharmacy:
Onco360 is the largest independent Oncology Pharmacy and
clinical support services company in the country. Onco360 was
founded in 2003 to bring together the stakeholders involved in the
cancer treatment process and serve the specialized needs of
oncologists, patients, hospitals, cancer centers of excellence,
manufacturers, health plans, and payers. It dispenses nationally
through its network of URAC, ACHC, and JCAHO-accredited Oncology
Pharmacies. Onco360 is headquartered in Louisville, KY, and is a
part of PharMerica Corporation (NYSE: PMC), a leading institutional
pharmacy, specialty infusion and hospital services company
servicing healthcare facilities in the United States. For more
information about Onco360 please visit www.Onco360.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171016006174/en/
PharMerica CorporationRobert Dries, 502-627-7140Executive Vice
President andChief Financial Officer
Pharmerica Corp. (delisted) (NYSE:PMC)
過去 株価チャート
から 5 2024 まで 6 2024
Pharmerica Corp. (delisted) (NYSE:PMC)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Pharmerica Corp. (delisted) (ニューヨーク証券取引所): 0 recent articles
その他のPharmerica Corp.ニュース記事